mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer.

[1]  Wei Li,et al.  Rapamycin together with herceptin significantly increased anti‐tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells , 2007, International journal of cancer.

[2]  G. Thomas,et al.  hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling. , 2007, Current Opinion in Cell Biology.

[3]  Timothy J. Griffin,et al.  Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 , 2007, Nature Cell Biology.

[4]  L. Ellisen,et al.  Dexamethasone Represses Signaling through the Mammalian Target of Rapamycin in Muscle Cells by Enhancing Expression of REDD1* , 2006, Journal of Biological Chemistry.

[5]  D. Guertin,et al.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. , 2006, Developmental cell.

[6]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[7]  Siobhan McCormack,et al.  Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors , 2006, Molecular Cancer Therapeutics.

[8]  M. Mouret-Reynier,et al.  Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. , 2006, Clinical breast cancer.

[9]  Jacob D. Jaffe,et al.  mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s , 2006, Current Biology.

[10]  Tony Hunter,et al.  Turnover of the Active Fraction of IRS1 Involves Raptor-mTOR- and S6K1-Dependent Serine Phosphorylation in Cell Culture Models of Tuberous Sclerosis , 2006, Molecular and Cellular Biology.

[11]  Rosa Bernardi,et al.  PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR , 2006, Nature.

[12]  H. Nawashiro,et al.  L‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumors , 2006, International journal of cancer.

[13]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[14]  D. Costa,et al.  Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib , 2006, Diabetes Care.

[15]  G. Thomas,et al.  Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. , 2006, Cell metabolism.

[16]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[17]  G. Thomas,et al.  The amino acid sensitive TOR pathway from yeast to mammals , 2006, FEBS letters.

[18]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[19]  George Thomas,et al.  Hypothalamic mTOR Signaling Regulates Food Intake , 2006, Science.

[20]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[21]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[22]  A. Morris,et al.  Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin , 2006, Diabetologia.

[23]  G. Sethuraman,et al.  Rapamycin causes regression of astrocytomas in tuberous sclerosis complex , 2006, Annals of neurology.

[24]  E. Shumay,et al.  G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation , 2006, Trends in Endocrinology & Metabolism.

[25]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[26]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[27]  S. Kimball,et al.  Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. , 2006, The Journal of nutrition.

[28]  B. Wolf,et al.  Leucine regulation of glucokinase and ATP synthase sensitizes glucose-induced insulin secretion in pancreatic beta-cells. , 2006, Diabetes.

[29]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[30]  C. Thompson,et al.  Akt-dependent transformation: there is more to growth than just surviving , 2005, Oncogene.

[31]  F. Natt,et al.  Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Y. Wang,et al.  Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development , 2005, Leukemia.

[33]  James T. Murray,et al.  hVps34 Is a Nutrient-regulated Lipid Kinase Required for Activation of p70 S6 Kinase* , 2005, Journal of Biological Chemistry.

[34]  Wolfgang Eiermann,et al.  Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Fuchs,et al.  Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? , 2005, Seminars in cancer biology.

[36]  C. Johannessen,et al.  Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1 , 2005, Molecular and Cellular Biology.

[37]  C. Johannessen,et al.  The NF1 tumor suppressor critically regulates TSC2 and mTOR. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Proud,et al.  The Tuberous Sclerosis Protein TSC2 Is Not Required for the Regulation of the Mammalian Target of Rapamycin by Amino Acids and Certain Cellular Stresses* , 2005, Journal of Biological Chemistry.

[39]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[40]  R O Morgan,et al.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study , 2005, Gut.

[41]  J. Blenis,et al.  Characterization of a Conserved C-terminal Motif (RSPRR) in Ribosomal Protein S6 Kinase 1 Required for Its Mammalian Target of Rapamycin-dependent Regulation* , 2005, Journal of Biological Chemistry.

[42]  H. Lane,et al.  The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.

[43]  E. Bonora,et al.  Imatinib and regression of type 2 diabetes. , 2005, The New England journal of medicine.

[44]  J. Best,et al.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.

[45]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[46]  S. Kuriyama,et al.  Obesity and risk of cancer in Japan , 2005, International journal of cancer.

[47]  F. McCormick,et al.  Cancer targets in the Ras pathway. , 2005, Cold Spring Harbor symposia on quantitative biology.

[48]  F. Mandelli,et al.  Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  H. El‐Serag,et al.  Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.

[50]  G. Thomas,et al.  Disruption of the Mouse mTOR Gene Leads to Early Postimplantation Lethality and Prohibits Embryonic Stem Cell Development , 2004, Molecular and Cellular Biology.

[51]  Y. Zick.  Uncoupling insulin signalling by serine/threonine phosphorylation: a molecular basis for insulin resistance. , 2004, Biochemical Society transactions.

[52]  M. Patti,et al.  Nutrient sensor links obesity with diabetes risk , 2004, Nature Medicine.

[53]  T. Hunter,et al.  Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.

[54]  Johan Auwerx,et al.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity , 2004, Nature.

[55]  M. Murakami,et al.  mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells , 2004, Molecular and Cellular Biology.

[56]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[57]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[58]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[59]  R. DePinho,et al.  Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. , 2004, Genes & development.

[60]  A. Prescott,et al.  The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation , 2004, The EMBO journal.

[61]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[63]  L. Cantley,et al.  Rheb fills a GAP between TSC and TOR. , 2003, Trends in biochemical sciences.

[64]  E. Giovannucci.  Nutrition, Insulin, Insulin-like Growth Factors and Cancer , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[65]  Y. Le Marchand-Brustel,et al.  Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. , 2003, Diabetes.

[66]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[67]  Paul Tempst,et al.  GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. , 2003, Molecular cell.

[68]  G. Thomas,et al.  Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. , 2002, Genes & development.

[69]  D. Hardie,et al.  A homologue of AMP-activated protein kinase in Drosophila melanogaster is sensitive to AMP and is activated by ATP depletion. , 2002, The Biochemical journal.

[70]  O. Hino,et al.  Tsc tumour suppressor proteins antagonize amino-acid–TOR signalling , 2002, Nature Cell Biology.

[71]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[72]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[73]  E. Hafen,et al.  dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1 , 2002, Nature cell biology.

[74]  R. Kaaks.  Nutrition, energy balance and colon cancer risk: the role of insulin and insulin-like growth factor-I. , 2002, IARC scientific publications.

[75]  A. Jaeschke,et al.  Mammalian TOR: A Homeostatic ATP Sensor , 2001, Science.

[76]  N. Thompson,et al.  Overexpression of LAT1/CD98 Light Chain Is Sufficient to Increase System l-Amino Acid Transport Activity in Mouse Hepatocytes but Not Fibroblasts* , 2001, The Journal of Biological Chemistry.

[77]  H. Adami,et al.  Overweight as an avoidable cause of cancer in Europe , 2001, International journal of cancer.

[78]  F. Ashcroft,et al.  A Novel Method for Measurement of Submembrane ATP Concentration* , 2000, The Journal of Biological Chemistry.

[79]  T. Masuko,et al.  Transformation of BALB3T3 cells caused by over‐expression of rat CD98 heavy chain (HC) requires its association with light chain: Mis‐sense mutation in a cysteine residue of CD98HC eliminates its transforming activity , 2000, International journal of cancer.

[80]  J. Dixon,et al.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase. , 1999, Trends in cell biology.

[81]  C. Shoemaker,et al.  Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family , 1998, Nature.

[82]  H. Adami,et al.  Diabetes mellitus and risk of large bowel cancer. , 1997, Journal of the National Cancer Institute.

[83]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[84]  B. Rosenlund.  Effects of insulin on free amino acids in plasma and the role of the amino acid metabolism in the etiology of diabetic microangiopathy. , 1993, Biochemical medicine and metabolic biology.

[85]  P. Felig,et al.  Splanchnic glucose and amino acid metabolism in obesity. , 1974, The Journal of clinical investigation.

[86]  D. Porte,et al.  Are plasma amino acid levels elevated in obesity? , 1970, The New England journal of medicine.

[87]  P. Felig,et al.  Plasma amino acid levels and insulin secretion in obesity. , 1969, The New England journal of medicine.